Shots:

• The P-III CheckMate-816 study involves assessing of Opdivo (360mg) + CT (q3w for 3 doses) vs CT (q3w for 3 doses)- followed by surgery as a neoadjuvant treatment in 358 patients with resectable NSCLC
• The study met its 1EPs of improved pathologic complete response. The positive results mark the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy as neoadjuvant therapy in a P-III trial in resectable NSCLC
• The study is ongoing to assess other 1EPs of EFS. Opdivo-based treatments demonstrated benefit in 4 P-III clinical trials in early-stage cancers- including lung cancer- bladder cancer- esophageal/gastroesophageal junction cancer- and melanoma

 ­ Ref: BMS | Image: BMS